Black Diamond Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a company specializing in precision oncology, announced that CEO David M. Epstein, Ph.D., will present updates on the company's progress at two upcoming investor conferences. The first presentation is at the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 4:40 PM ET. The second will be available on-demand at the Jefferies London Healthcare Conference starting November 18, 2021. Webcasts of the presentations will be accessible on the company's investor relations website.

CAMBRIDGE, Mass. and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the following upcoming investor conferences:

• The Stifel 2021 Virtual Healthcare Conference. The corporate presentation will take place on Monday, November 15, 2021 at 4:40 PM ET.
• The 2021 Jefferies London Healthcare Conference. The presentation will be available on-demand beginning Thursday, November 18, 2021, starting at 4:00 AM ET.

A webcast of the Stifel presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of each presentation will also be available and archived on the site for 30 days.

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of MasterKey therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform and drug discovery engine, the Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy that targets a specific family of mutations, termed a MasterKey therapy. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts
For Investors:
Natalie Wildenradt
investors@bdtx.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtx.com

FAQ

What is Black Diamond Therapeutics presenting at the Stifel 2021 Virtual Healthcare Conference?

Black Diamond Therapeutics will provide an update on the company's progress during the Stifel 2021 Virtual Healthcare Conference on November 15, 2021.

When can I access the Black Diamond Therapeutics presentation at the Jefferies London Healthcare Conference?

The presentation by Black Diamond Therapeutics will be available on-demand starting November 18, 2021, at 4:00 AM ET.

How can I watch the Black Diamond Therapeutics investor presentations?

Webcasts of the Black Diamond Therapeutics presentations can be accessed through the investor relations section of their website.

What is the focus of Black Diamond Therapeutics?

Black Diamond Therapeutics focuses on developing MasterKey therapies targeting undrugged mutations in genetically defined cancers.

Who is the CEO of Black Diamond Therapeutics?

David M. Epstein, Ph.D., serves as the President and CEO of Black Diamond Therapeutics.